Our Healthcare business aims to change lives
With a holistic approach, we design and develop medicines and intelligent devices that strive to provide ongoing care for patients beyond their treatment. This includes medications to treat conditions such as cancer or multiple sclerosis (MS). For example, we offer an injection device and disease monitoring software outside USA and Canada that allow patients with MS to self-inject their medicine and track its administration. With cancer, we are researching the use of biomarkers that can match potential treatment to individual patients.
Our goal is to support people at various stages of life. We have helped many women and couples achieve their dream of having a baby. As a global market leader in fertility treatments, we do what we do with passion – and we think further ahead. That’s why we complemented our legacy in fertility drug treatments with the launch of a dedicated Fertility Technologies unit to help improve treatment outcomes in the lab.
Our purpose. Our patients.
We are united As One for Patients to help create, improve and prolong lives.
This is our purpose – the reason why we do what we do every day. Working As One for Patients motivates us to always give our best and continuously improve our efforts.
Because we understand that every single one of us, every decision and contribution we make in our work has an impact on the lives of patients and their caregivers.
We are united As One for Patients.
As One for Patients
At Healthcare, we’re on a mission: to help patients.
Our therapeutic areas
In 2018, it is estimated that more than 9.5 million people died from cancer and that number is expected to increase.
Neurology & Immunology
We have more than 20 years of experience in Multiple Sclerosis (MS) care, and remain committed to finding solutions for patients’ significant unmet needs.
We combine our expertise in diabetes, cardiovascular diseases and thyroid disorders to provide access to healthcare solutions.
With our broad portfolio of treatment options, devices and advanced fertility technologies, we aim to contribute to improved treatment outcomes that help couples fulfill the dream of parenthood.
Related NewsView All News
Merck KGaA, Darmstadt, Germany today announced new real-world data that continue to reinforce the JAVELIN Bladder regimen as a standard of care.
Merck KGaA, Darmstadt, Germany enters licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), in development for advanced colorectal cancer.
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for arpraziquantel.
This publication is intended to provide information to an international audience. Not all products discussed on this page may be available in your country and local prescribing information and approved indications may differ from country to country. For local prescribing information and approved indications, please visit our local websites.